Is LENZ or VERU more profitable?

Veru has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -586.74%. Veru's return on equity of -47.58% beat LENZ Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets LENZ Therapeutics -586.74% -53.39% -49.14% Veru N/A -47.58% -35.83%

Does the media favor LENZ or VERU?

In the previous week, Veru had 2 more articles in the media than LENZ Therapeutics. MarketBeat recorded 6 mentions for Veru and 4 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 1.04 beat Veru's score of 0.16 indicating that LENZ Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veru 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is NRXP or VERU more profitable?

Veru has a net margin of 0.00% compared to NRx Pharmaceuticals' net margin of -691.81%. NRx Pharmaceuticals' return on equity of 0.00% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets NRx Pharmaceuticals -691.81% N/A -63.92% Veru N/A -47.58% -35.83%

Does the media favor NRXP or VERU?

In the previous week, NRx Pharmaceuticals had 2 more articles in the media than Veru. MarketBeat recorded 8 mentions for NRx Pharmaceuticals and 6 mentions for Veru. NRx Pharmaceuticals' average media sentiment score of 0.61 beat Veru's score of 0.16 indicating that NRx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veru 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is UNCY or VERU more profitable?

Veru's return on equity of -47.58% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Unicycive Therapeutics N/A -91.50% -61.47% Veru N/A -47.58% -35.83%

Does the media prefer UNCY or VERU?

In the previous week, Unicycive Therapeutics had 23 more articles in the media than Veru. MarketBeat recorded 29 mentions for Unicycive Therapeutics and 6 mentions for Veru. Veru's average media sentiment score of 0.16 beat Unicycive Therapeutics' score of -0.01 indicating that Veru is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 21 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Veru 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is VERU or MIST more profitable?

Veru's return on equity of -47.58% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% Milestone Pharmaceuticals N/A -288.33% -58.27%

Veru (VERU) Competitors

$2.44 -0.06 (-2.40%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.44 +0.00 (+0.20%)

As of 09/11/2026 07:59 PM Eastern

Compare

VERU vs. LFCR, LENZ, NRXP, UNCY, and MIST

Should you buy Veru stock or one of its competitors? Veru's main competitors and comparable companies include Lifecore Biomedical (LFCR), LENZ Therapeutics (LENZ), NRx Pharmaceuticals (NRXP), Unicycive Therapeutics (UNCY), and Milestone Pharmaceuticals (MIST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Veru compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Veru has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Veru	N/A	-47.58%	-35.83%

Veru has lower revenue, but higher earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.21	-$40.50M	-$1.07	N/A
Veru	N/A	N/A	-$22.73M	-$0.69	N/A

In the previous week, Veru had 5 more articles in the media than Lifecore Biomedical. MarketBeat recorded 6 mentions for Veru and 1 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.83 beat Veru's score of 0.16 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Lifecore Biomedical	Very Positive
Veru	Neutral

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by insiders. Comparatively, 14.2% of Veru shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lifecore Biomedical has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Veru has a beta of -1.17, indicating that its stock price is 217% less volatile than the broader market.

Lifecore Biomedical currently has a consensus target price of $6.50, indicating a potential upside of 57.77%. Veru has a consensus target price of $24.50, indicating a potential upside of 904.10%. Given Veru's stronger consensus rating and higher probable upside, analysts clearly believe Veru is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Veru beats Lifecore Biomedical on 8 of the 15 factors compared between the two stocks.

How does Veru compare to LENZ Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

Veru has lower revenue, but higher earnings than LENZ Therapeutics. Veru is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	7.44	-$82.13M	-$4.09	N/A
Veru	N/A	N/A	-$22.73M	-$0.69	N/A

LENZ Therapeutics currently has a consensus target price of $28.80, indicating a potential upside of 537.17%. Veru has a consensus target price of $24.50, indicating a potential upside of 904.10%. Given Veru's higher probable upside, analysts plainly believe Veru is more favorable than LENZ Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Veru has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -586.74%. Veru's return on equity of -47.58% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-586.74%	-53.39%	-49.14%
Veru	N/A	-47.58%	-35.83%

LENZ Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, Veru has a beta of -1.17, suggesting that its share price is 217% less volatile than the broader market.

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by insiders. Comparatively, 14.2% of Veru shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Veru had 2 more articles in the media than LENZ Therapeutics. MarketBeat recorded 6 mentions for Veru and 4 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 1.04 beat Veru's score of 0.16 indicating that LENZ Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENZ Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veru	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Veru beats LENZ Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Veru compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Veru has a net margin of 0.00% compared to NRx Pharmaceuticals' net margin of -691.81%. NRx Pharmaceuticals' return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	-691.81%	N/A	-63.92%
Veru	N/A	-47.58%	-35.83%

In the previous week, NRx Pharmaceuticals had 2 more articles in the media than Veru. MarketBeat recorded 8 mentions for NRx Pharmaceuticals and 6 mentions for Veru. NRx Pharmaceuticals' average media sentiment score of 0.61 beat Veru's score of 0.16 indicating that NRx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NRx Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veru	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Veru has lower revenue, but higher earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	119.69	-$28.62M	-$0.55	N/A
Veru	N/A	N/A	-$22.73M	-$0.69	N/A

NRx Pharmaceuticals currently has a consensus price target of $34.50, indicating a potential upside of 914.71%. Veru has a consensus price target of $24.50, indicating a potential upside of 904.10%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe NRx Pharmaceuticals is more favorable than Veru.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by insiders. Comparatively, 14.2% of Veru shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

NRx Pharmaceuticals has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market. Comparatively, Veru has a beta of -1.17, meaning that its share price is 217% less volatile than the broader market.

Summary

NRx Pharmaceuticals beats Veru on 9 of the 15 factors compared between the two stocks.

How does Veru compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

In the previous week, Unicycive Therapeutics had 23 more articles in the media than Veru. MarketBeat recorded 29 mentions for Unicycive Therapeutics and 6 mentions for Veru. Veru's average media sentiment score of 0.16 beat Unicycive Therapeutics' score of -0.01 indicating that Veru is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	21 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Veru	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Veru's return on equity of -47.58% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
Veru	N/A	-47.58%	-35.83%

Unicycive Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market. Comparatively, Veru has a beta of -1.17, meaning that its share price is 217% less volatile than the broader market.

Unicycive Therapeutics presently has a consensus price target of $18.75, indicating a potential upside of 254.44%. Veru has a consensus price target of $24.50, indicating a potential upside of 904.10%. Given Veru's higher possible upside, analysts clearly believe Veru is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by insiders. Comparatively, 14.2% of Veru shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Veru has lower revenue, but higher earnings than Unicycive Therapeutics. Veru is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	216.66	-$26.56M	-$1.75	N/A
Veru	N/A	N/A	-$22.73M	-$0.69	N/A

Summary

Veru beats Unicycive Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Veru compare to Milestone Pharmaceuticals?

Veru (NASDAQ:VERU) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Veru presently has a consensus price target of $24.50, suggesting a potential upside of 904.10%. Milestone Pharmaceuticals has a consensus price target of $6.40, suggesting a potential upside of 552.99%. Given Veru's higher probable upside, analysts plainly believe Veru is more favorable than Milestone Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Veru had 5 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 6 mentions for Veru and 1 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 0.62 beat Veru's score of 0.16 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Veru	Neutral
Milestone Pharmaceuticals	Positive

Veru has higher earnings, but lower revenue than Milestone Pharmaceuticals. Veru is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	N/A	N/A	-$22.73M	-$0.69	N/A
Milestone Pharmaceuticals	$1.55M	78.72	-$63.06M	-$0.69	N/A

Veru's return on equity of -47.58% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%

Veru has a beta of -1.17, meaning that its share price is 217% less volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

47.2% of Veru shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 14.2% of Veru shares are held by insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Milestone Pharmaceuticals beats Veru on 8 of the 14 factors compared between the two stocks.

Get Veru News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERU vs. The Competition

Export

Metric	Veru	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$41.60M	$12.41B	$7.16B	$12.85B
Dividend Yield	N/A	2.63%	2.57%	11.72%
P/E Ratio	-3.54	799.75	274.94	25.36
Price / Sales	N/A	960.74	685.43	116.38
Price / Cash	N/A	88.17	76.65	51.52
Price / Book	1.95	10.39	10.33	6.20
Net Income	-$22.73M	$2.85B	$3.50B	$358.50M
7 Day Performance	-7.58%	-3.61%	-3.32%	-2.35%
1 Month Performance	-9.63%	0.72%	-0.53%	-3.23%
1 Year Performance	-29.28%	3.61%	23.51%	8.79%

Veru Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERU Veru	2.7004 of 5 stars	$2.44 -2.4%	$24.50 +904.1%	-29.3%	$41.60M	N/A	N/A	230
LFCR Lifecore Biomedical	1.7626 of 5 stars	$4.46 -1.8%	$6.50 +45.7%	-45.2%	$171.85M	$128.87M	N/A	690	Analyst Upgrade
LENZ LENZ Therapeutics	3.2296 of 5 stars	$5.21 +2.0%	$28.80 +452.8%	-89.1%	$160.56M	$19.09M	N/A	110	Positive News Analyst Downgrade
NRXP NRx Pharmaceuticals	1.7531 of 5 stars	$3.48 -2.0%	$34.50 +891.4%	+21.4%	$153.70M	$1.23M	N/A	2	News Coverage
UNCY Unicycive Therapeutics	3.0201 of 5 stars	$5.20 -1.1%	$18.75 +260.6%	+36.7%	$146.66M	$680K	N/A	9	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERU) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veru (VERU) Competitors

VERU vs. LFCR, LENZ, NRXP, UNCY, and MIST

How does Veru compare to Lifecore Biomedical?

Summary

How does Veru compare to LENZ Therapeutics?

Summary

How does Veru compare to NRx Pharmaceuticals?

Summary

How does Veru compare to Unicycive Therapeutics?

Summary

How does Veru compare to Milestone Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERU vs. The Competition

Veru Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veru (VERU) Competitors

VERU vs. LFCR, LENZ, NRXP, UNCY, and MIST

How does Veru compare to Lifecore Biomedical?

Is LFCR or VERU more profitable?

Which has better earnings and valuation, LFCR or VERU?

Does the media favor LFCR or VERU?

Do institutionals and insiders believe in LFCR or VERU?

Which has more volatility and risk, LFCR or VERU?

Do analysts rate LFCR or VERU?

Summary

How does Veru compare to LENZ Therapeutics?

Which has preferable valuation & earnings, LENZ or VERU?

Do analysts recommend LENZ or VERU?

Is LENZ or VERU more profitable?

Which has more risk and volatility, LENZ or VERU?

Do insiders & institutionals have more ownership in LENZ or VERU?

Does the media favor LENZ or VERU?

Summary

How does Veru compare to NRx Pharmaceuticals?

Is NRXP or VERU more profitable?

Does the media favor NRXP or VERU?

Which has better earnings & valuation, NRXP or VERU?

Do analysts prefer NRXP or VERU?

Do institutionals & insiders believe in NRXP or VERU?

Which has more volatility and risk, NRXP or VERU?

Summary

How does Veru compare to Unicycive Therapeutics?

Does the media prefer UNCY or VERU?

Is UNCY or VERU more profitable?

Which has more volatility & risk, UNCY or VERU?

Do analysts prefer UNCY or VERU?

Do insiders & institutionals have more ownership in UNCY or VERU?

Which has stronger earnings and valuation, UNCY or VERU?

Summary

How does Veru compare to Milestone Pharmaceuticals?

Do analysts prefer VERU or MIST?

Does the media prefer VERU or MIST?

Which has higher valuation & earnings, VERU or MIST?

Is VERU or MIST more profitable?

Which has more risk and volatility, VERU or MIST?

Do institutionals and insiders hold more shares of VERU or MIST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERU vs. The Competition

Veru Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools